RxDoctor Payments Data

Rajani Rudrangi, MD

Internal Medicine · French Camp, CANPI 1487841482

Payments from drug & device makers

$759in general payments, 2019–2025

Across 44 payments — averaging $17.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$352
  • GSK$238
  • Pfizer$103
  • Novartis$28
  • Amgen$23
  • Johnson & Johnson$16

What the payments were for

  • Food & beverage$74798%
  • Education$122%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie23$352
GSK12$238
Pfizer4$103
Novartis2$28
Amgen2$23
Johnson & Johnson1$16

How this compares

$759 in reported general payments places this provider in the 70th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$30,229
Medicare patients
132
Services billed
304

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Enbrel SureclickEtanercept26$198,419
Humira(Cf) PenAdalimumab19$130,763
Orencia ClickjectAbatacept11$98,152
RinvoqUpadacitinib13$81,110
Taltz AutoinjectorIxekizumab12$73,395
Cimzia (2 Pack)Certolizumab Pegol12$65,639
Hydroxychloroquine Sulfate128$4,344
Mycophenolate Mofetil20$2,421
MethotrexateMethotrexate Sodium57$2,190
Leflunomide20$1,853
Colchicine17$1,619
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen38$941
Sulfasalazine DrSulfasalazine18$804
Prednisone103$590
Diclofenac Sodium20$268

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRinvoq$352$81,11013 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 13,581 internal medicine providers in California.

Other internal medicine in French Camp

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →